Please assess the completion status of the following clinical trial:

Trial Title: Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic phase Ph\^+ chronic myeloid leukemia (CML) demonstrating only a suboptimal response, defined as a hematologic response that is less than a complete hematologic response after at least 3 months of monotherapy with imatinib, 400 mg; a cytogenic response (CgR) that is less than a partial CgR (PCgR) after at least 6 months of monotherapy with imatinib, 400 mg; a PCgR after at least 12 months of monotherapy with imatinib, 400 mg; or less than a major molecular response with a complete CgR after at least 18 months of monotherapy with imatinib, 400 mg.~* Either gender~* Age of 18 years or older~Exclusion Criteria:~* Previous diagnosis of accelerated phase or blast crisis CML~* Uncontrolled or significant cardiovascular disease~* History of significant bleeding disorder unrelated to CML~* Concurrent malignancies~* Intolerance of imatinib, 400 mg~* Prior treatment with imatinib at a dose higher than 400 mg~* Prior stem cell transplantation and/or high-dose chemotherapy for CML

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib (Type: ACTIVE_COMPARATOR): Participants with chronic phase chronic myeloid leukemia (CML) who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
- Imatinib (Type: ACTIVE_COMPARATOR): Participants with chronic phase CML who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).